Topic
Minimal Residual Disease (MRD)
2 Podcasts on BackTable
Episode # 76 • 11 Aug 2026
GU Oncology: ASCO Highlights & Impacts on Practice
Is GU oncology entering a new era of early intensification and precision therapy? On this episode of the BackTable Tumor Board Podcast, Dr. Katy Beckermann and Dr. Alan Tan break down the latest GU oncology highlights from ASCO, including key updates in prostate, renal cell, and urothelial carcinoma. They discuss new data supporting HRR/BRCA-focused therapy in HSPC, the importance of early biomarker testing, and ongoing debates about overtreatment and real-world practice impact.
More on Minimal Residual Disease (MRD)
Loading recent podcasts…
Tumor Board # 76
Aug 10, 2026
with Dr. Alan Tan, Dr. Katy Beckermann
Is GU oncology entering a new era of early intensification and precision therapy? On this episode of the BackTable...
Tumor Board # 43
Jan 12, 2026
with Dr. Jun Gong, Dr. Jonathan Mizrahi
Get caught up on the cutting edge colorectal cancer trial data from ESMO 2025 with this 30-minute BackTable Tumor Board...
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.